Regorafenib

Regorafenib Reactions 1680, p295 - 2 Dec 2017 Various toxicities: 10 case reports A retrospective study described 10 patients (including a 40-year-old woman) [ages and sexes of other patients not stated], who developed anaemia, anorexia, diarrhoea, hand- foot skin reaction, hypertension, hypoalbuminaemia, hypophosphataemia, hypothyroidism, malaise, neutropenia, proteinuria, thrombocytopenia, weight loss or increased lipase during treatment with regorafenib [time to reactions onsets not stated]. All the ten patients had a medical history of unresectable hepatocellular carcinoma. All the patients had undergone a prior treatment with sorafenib which was discontinued due to disease progression. Later, all the ten patients were started on treatment with oral regorafenib 160mg once daily for 3 weeks in each 4 week cycle with best supportive care. Subsequently, they developed grade 2 hypoalbuminaemia, grade 3 hypophosphataemia, grade 2 weight loss and grade 2 anorexia (1 patient); grade 3 hand-foot skin reaction and grade 3 hypertension (1 patient); grade 2 proteinuria and grade 2 malaise (1 patient); grade 2 anorexia and grade 3 lipase increased (1 patient); grade 3 proteinuria, grade 3 hypertension, grade 2 hypothyroidism, grade 2 anorexia, grade 2 anaemia, grade 3 hypophosphataemia or grade 2 thrombocytopenia (1 patient); grade 2 diarrhoea and grade 2 anorexia (1 patient); grade 2 malaise and grade 1 anorexia (1 patient); grade 2 thrombocytopenia or grade 3 neutropenia (1 patient); grade 1 hand-foot skin reaction, grade 2 malaise, grade 3 thrombocytopenia and grade 3 neutropenia (1 patient), and one patient developed grade 3 hand-foot skin reaction. All treatment-related adverse events were improved by the reduction or interruption of regorafenib treatment. Author comment: "In this study, we investigated the efficacy and safety of regorafenib". "The drug-related adverse events are summarized. . . Grade 3 hypophosphatemia without symptoms was observed in 2 patients, grade 2 anorexia was observed in 5 patients, and grade 3 neutropenia was observed in 2 patients. Grade 2 and grade 3 thrombocytopenia were observed in 2 and 3 patients, respectively." Ueshima K, et al. Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience. Digestive Diseases 35: 611-617, No. 6, Oct 2017. Available from: URL: http://doi.org/10.1159/000480257 - Japan 803285178 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Regorafenib

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/regorafenib-o1P0v0BDz0
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39226-5
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p295 - 2 Dec 2017 Various toxicities: 10 case reports A retrospective study described 10 patients (including a 40-year-old woman) [ages and sexes of other patients not stated], who developed anaemia, anorexia, diarrhoea, hand- foot skin reaction, hypertension, hypoalbuminaemia, hypophosphataemia, hypothyroidism, malaise, neutropenia, proteinuria, thrombocytopenia, weight loss or increased lipase during treatment with regorafenib [time to reactions onsets not stated]. All the ten patients had a medical history of unresectable hepatocellular carcinoma. All the patients had undergone a prior treatment with sorafenib which was discontinued due to disease progression. Later, all the ten patients were started on treatment with oral regorafenib 160mg once daily for 3 weeks in each 4 week cycle with best supportive care. Subsequently, they developed grade 2 hypoalbuminaemia, grade 3 hypophosphataemia, grade 2 weight loss and grade 2 anorexia (1 patient); grade 3 hand-foot skin reaction and grade 3 hypertension (1 patient); grade 2 proteinuria and grade 2 malaise (1 patient); grade 2 anorexia and grade 3 lipase increased (1 patient); grade 3 proteinuria, grade 3 hypertension, grade 2 hypothyroidism, grade 2 anorexia, grade 2 anaemia, grade 3 hypophosphataemia or grade 2 thrombocytopenia (1 patient); grade 2 diarrhoea and grade 2 anorexia (1 patient); grade 2 malaise and grade 1 anorexia (1 patient); grade 2 thrombocytopenia or grade 3 neutropenia (1 patient); grade 1 hand-foot skin reaction, grade 2 malaise, grade 3 thrombocytopenia and grade 3 neutropenia (1 patient), and one patient developed grade 3 hand-foot skin reaction. All treatment-related adverse events were improved by the reduction or interruption of regorafenib treatment. Author comment: "In this study, we investigated the efficacy and safety of regorafenib". "The drug-related adverse events are summarized. . . Grade 3 hypophosphatemia without symptoms was observed in 2 patients, grade 2 anorexia was observed in 5 patients, and grade 3 neutropenia was observed in 2 patients. Grade 2 and grade 3 thrombocytopenia were observed in 2 and 3 patients, respectively." Ueshima K, et al. Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience. Digestive Diseases 35: 611-617, No. 6, Oct 2017. Available from: URL: http://doi.org/10.1159/000480257 - Japan 803285178 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off